Gordian Biotechnology

Biotech startup focused on age-related diseases

South San Francisco, California, United States

About Gordian Biotechnology

Gordian Biotechnology focuses on developing treatments for age-related diseases through drug discovery. The company uses advanced technologies to create models that accurately reflect the biological processes of aging, which helps in testing therapies in conditions similar to those in humans. This method increases the chances of success in clinical trials. Gordian Bio primarily collaborates with pharmaceutical companies, research institutions, and healthcare providers, generating revenue through partnerships and licensing agreements. Their goal is to extend healthy human lifespan by addressing the underlying causes of age-related diseases. They utilize animal models, like fruit flies, to study aging and test new therapies, allowing for scalable and precise research. The team consists of experts in gene therapy and genome engineering, and their work has been recognized at major industry conferences.

South San Francisco, CaliforniaHeadquarters
1990Year Founded
$58.4MTotal Funding
EARLY_VCCompany Stage
Biotechnology, HealthcareIndustries
11-50Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Remote Work Options
Meal Benefits
Gym Membership

Risks

Reliance on animal models may face ethical scrutiny and regulatory challenges.
Dependence on advanced technologies exposes Gordian to risks of obsolescence and supply chain issues.
Niche focus on age-related diseases might limit market opportunities and funding availability.

Differentiation

Gordian Bio uses 'patient avatars' for drug testing, mimicking human conditions closely.
Their high-throughput in vivo screening platform tests hundreds of gene therapies simultaneously.
Gordian Bio focuses on age-related diseases, a niche yet critical segment in biotech.

Upsides

Increased interest in personalized medicine aligns with Gordian's screening capabilities.
Growing focus on longevity research attracts investment, benefiting Gordian's funding opportunities.
Collaborations with academic institutions offer research partnerships and scientific insights.

Funding

Total raised$58.36 M
Latest valuation$300.00 M
StageEARLY_VC